Two founder mutations in the alpha-tropomyosin and the cardiac myosin-binding protein C genes are common causes of hypertrophic cardiomyopathy in the Finnish population

Myofilament Protein Gene Mutation Screening and Outcome of Patients With Hypertrophic Cardiomyopathy

(2012) Iacopo Olivotto et al.   MAYO CLINIC PROCEEDINGS

Founder mutations in hypertrophic cardiomyopathy patients in the Netherlands

(2011) I. Christiaans* et al.   Netherlands Heart Journal

Recurrent and founder mutations in the Netherlands: cardiac Troponin I (TNNI3) gene mutations as a cause of severe forms of hypertrophic and restrictive cardiomyopathy

(2011) A. van den Wijngaard et al.   Netherlands Heart Journal

Mutation Type Is Not Clinically Useful in Predicting Prognosis in Hypertrophic Cardiomyopathy

(2010) Andrew P. Landstrom et al.   CIRCULATION

Genetics and Clinical Destiny: Improving Care in Hypertrophic Cardiomyopathy

(2010) Carolyn Y. Ho   CIRCULATION

Insights into genotype-phenotype correlation in hypertrophic cardiomyopathy. Findings from 18 Spanish families with a single mutation in MYBPC3

(2010) M. J. Oliva-Sandoval et al.   HEART

High prevalence of four long QT syndrome founder mutations in the Finnish population

(2009) Annukka Marjamaa et al.   ANNALS OF MEDICINE

Cardiac Myosin-Binding Protein C Mutations and Hypertrophic Cardiomyopathy

(2009) Sabine J. van Dijk et al.   CIRCULATION

Disease penetrance and risk stratification for sudden cardiac death in asymptomatic hypertrophic cardiomyopathy mutation carriers

(2009) Michelle Michels et al.   EUROPEAN HEART JOURNAL

Diagnostic yield, interpretation, and clinical utility of mutation screening of sarcomere encoding genes in Danish hypertrophic cardiomyopathy patients and relatives

(2008) Paal Skytt Andersen et al.   HUMAN MUTATION